🍽️ rabeprazole sodium salt,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Gastroesophageal Reflux Disease (GERD): Rabeprazole is highly effective in treating GERD, a condition characterized by the backward flow of stomach acid into the esophagus, causing symptoms such as heartburn, regurgitation, and chest pain.

  2. Peptic Ulcers: Rabeprazole is used to treat peptic ulcers, including gastric ulcers (in the stomach) and duodenal ulcers (in the upper part of the small intestine). It helps promote ulcer healing and prevents their recurrence by reducing stomach acid production.

  3. Helicobacter pylori Eradication: Rabeprazole is often prescribed as part of a combination therapy to eradicate Helicobacter pylori bacteria, which can contribute to the development of ulcers and gastritis.

  4. Gastritis: Rabeprazole can help alleviate the symptoms of gastritis, an inflammation of the stomach lining often caused by excessive stomach acid production or Helicobacter pylori infection.

  5. Zollinger-Ellison Syndrome: This rare condition is characterized by the overproduction of stomach acid, leading to severe ulcers in the stomach and small intestine. Rabeprazole is used to manage symptoms and reduce acid secretion in patients with Zollinger-Ellison syndrome.

  6. Non-Ulcer Dyspepsia: Rabeprazole may be prescribed to alleviate symptoms of non-ulcer dyspepsia, including upper abdominal pain, bloating, and discomfort, particularly when these symptoms are related to excess stomach acid.

  7. Prevention of NSAID-Induced Ulcers: Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause gastrointestinal ulcers and bleeding. Rabeprazole is sometimes prescribed to individuals taking NSAIDs long-term to reduce the risk of ulcers and associated complications.

  8. Reflux Esophagitis: Rabeprazole is effective in treating reflux esophagitis, a condition characterized by inflammation and damage to the esophagus due to repeated exposure to stomach acid.

  9. Barrett's Esophagus: Rabeprazole may be used as part of the treatment plan for Barrett's esophagus, a complication of GERD characterized by changes in the lining of the esophagus that may increase the risk of esophageal cancer.

  10. Eosinophilic Esophagitis: In some cases, rabeprazole may be prescribed as part of the management of eosinophilic esophagitis, an allergic inflammatory condition of the esophagus that can cause difficulty swallowing and other symptoms.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of rabeprazole sodium salt,(prescription) On Probiotics

Rank Probiotic Impact
species Bifidobacterium adolescentis Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by rabeprazole sodium salt,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Blautia genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Mediterraneibacter genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Escherichia genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Lacticaseibacillus genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Blautia obeum species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Parabacteroides distasonis species Decreases 📓 Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Streptococcus parasanguinis species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Lachnospira eligens species Decreases 📓 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Enterocloster bolteae species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Lactonifactor longoviformis species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Anaerosporobacter mobilis species Decreases ⚗️ Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Bifidobacterium adolescentis species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of rabeprazole sodium salt,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.5 0.5
Acne 0 0
ADHD 2.7 0.5 4.4
Age-Related Macular Degeneration and Glaucoma 1 0.5 1
Allergic Rhinitis (Hay Fever) 2.6 0.1 25
Allergies 4.2 1.9 1.21
Allergy to milk products 2.1 1 1.1
Alopecia (Hair Loss) 2.2 2.2
Alzheimer's disease 5.4 7.4 -0.37
Amyotrophic lateral sclerosis (ALS) Motor Neuron 3 1.4 1.14
Ankylosing spondylitis 4.2 2.5 0.68
Anorexia Nervosa 0.5 3.1 -5.2
Antiphospholipid syndrome (APS) 2.2 0.5 3.4
Asthma 0.5 0.7 -0.4
Atherosclerosis 1.2 2 -0.67
Atrial fibrillation 3.8 2 0.9
Autism 8.9 8.9 0
Barrett esophagus cancer 0.5 0.2 1.5
benign prostatic hyperplasia 0.5 0.5
Bipolar Disorder 2.1 1.5 0.4
Brain Trauma 0.3 0.7 -1.33
Cancer (General) 1.5 -1.5
Carcinoma 3.6 2.5 0.44
Celiac Disease 2.1 3.1 -0.48
Cerebral Palsy 0.8 1.7 -1.13
Chronic Fatigue Syndrome 6.1 9 -0.48
Chronic Kidney Disease 3.1 2.6 0.19
Chronic Lyme 0.7 -0.7
Chronic Obstructive Pulmonary Disease (COPD) 1.7 1.3 0.31
Chronic Urticaria (Hives) 2.1 1.2 0.75
Coagulation / Micro clot triggering bacteria 2.1 1.7 0.24
Colorectal Cancer 5.5 0.8 5.88
Constipation 1.7 1 0.7
Coronary artery disease 2.2 1 1.2
COVID-19 8.1 10.9 -0.35
Crohn's Disease 9.1 6.8 0.34
cystic fibrosis 1.4 0.8 0.75
deep vein thrombosis 1.4 1.2 0.17
Depression 7.7 8.4 -0.09
Dermatomyositis 0.2 0 0
Eczema 1.4 1.7 -0.21
Endometriosis 3.9 0.8 3.88
Eosinophilic Esophagitis 0.5 0.5
Epilepsy 3 2.2 0.36
Fibromyalgia 3.5 2.3 0.52
Functional constipation / chronic idiopathic constipation 6 3.9 0.54
gallstone disease (gsd) 2.9 1 1.9
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 2 1.2 0.67
Generalized anxiety disorder 3.3 1.3 1.54
giant cell arteritis 0.5 -0.5
Glioblastoma 0.2 -0.2
Gout 0.5 -0.5
Graves' disease 1 1.7 -0.7
Halitosis 0.7 0.2 2.5
Hashimoto's thyroiditis 2.8 0.8 2.5
Hidradenitis Suppurativa 1.2 1.2
Histamine Issues 2.9 1.5 0.93
hypercholesterolemia (High Cholesterol) 0.5 0.5
hyperglycemia 0.5 1.3 -1.6
Hyperlipidemia (High Blood Fats) 0.3 0.2 0.5
hypersomnia 1 -1
hypertension (High Blood Pressure 2.2 3.4 -0.55
Hypothyroidism 1 -1
Hypoxia 0.7 0.7
IgA nephropathy (IgAN) 2.7 -2.7
Inflammatory Bowel Disease 4.1 9.2 -1.24
Insomnia 1 1.1 -0.1
Intelligence 1.1 0.3 2.67
Intracranial aneurysms 1.7 0.2 7.5
Irritable Bowel Syndrome 3.1 2.4 0.29
Liver Cirrhosis 5.4 3.5 0.54
Long COVID 6.5 8.5 -0.31
Low bone mineral density 1.3 -1.3
Lung Cancer 0.5 1.5 -2
Mast Cell Issues / mastitis 0.7 1 -0.43
ME/CFS with IBS 1 3.3 -2.3
ME/CFS without IBS 1.8 2.7 -0.5
Menopause 0.1 0.1
Metabolic Syndrome 8.7 6.7 0.3
Mood Disorders 10.3 8.4 0.23
multiple chemical sensitivity [MCS] 0.3 0.5 -0.67
Multiple Sclerosis 4.2 7.2 -0.71
Multiple system atrophy (MSA) 0.9 1 -0.11
neuropathic pain 0.6 -0.6
Neuropathy (all types) 0.7 0.5 0.4
neuropsychiatric disorders (PANDAS, PANS) 0.9 0.9
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 2.8 4.2 -0.5
NonCeliac Gluten Sensitivity 0 0
Obesity 8.5 3.9 1.18
obsessive-compulsive disorder 6.3 4.6 0.37
Osteoarthritis 2.5 0.5 4
Osteoporosis 1.7 0.7 1.43
pancreatic cancer 0.2 0.2
Parkinson's Disease 2.8 5.8 -1.07
Polycystic ovary syndrome 3.3 2 0.65
Postural orthostatic tachycardia syndrome 0.5 0.5 0
Premenstrual dysphoric disorder 0.8 0.5 0.6
primary biliary cholangitis 0.5 0.4 0.25
Psoriasis 4.9 3 0.63
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 7.6 3.8 1
Rosacea 1.5 1 0.5
Schizophrenia 4.5 2.5 0.8
scoliosis 0.5 1.7 -2.4
Sjögren syndrome 2 2.5 -0.25
Sleep Apnea 2 1.7 0.18
Small Intestinal Bacterial Overgrowth (SIBO) 1.6 1.6
Stress / posttraumatic stress disorder 3.6 1.5 1.4
Systemic Lupus Erythematosus 5.1 1.9 1.68
Tic Disorder 1.2 1.1 0.09
Tourette syndrome 0.2 -0.2
Type 1 Diabetes 4.2 2.3 0.83
Type 2 Diabetes 8.9 7 0.27
Ulcerative colitis 3.6 3.9 -0.08
Unhealthy Ageing 6.6 2 2.3

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [34.239.170 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [34.239.170 ]